AstraZeneca’s gout drug wins faint praise from FDA advisers

Damian Garde

A majority of independent FDA recommended approval for AstraZeneca's new , but not without noting that the treatment's safety profile presents considerable concerns going forward.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS